Japan Group Plans Development Of Next-Generation Vaccine Adjuvants
This article was originally published in PharmAsia News
Executive Summary
A planning group that includes Japan's Daiichi Sankyo expects to hold its first meeting in November with a five-year goal of developing new adjuvants and closing the gap in vaccine development between Japan and the West